FH-MCVA2TCR T-cell therapy (bluebird bio/Fred Hutchinson Cancer Research Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFH-MCVA2TCR T-cell therapy (bluebird bio/Fred Hutchinson Cancer Research Center)
Drug Alias NameMerkel Cell Polyomavirus specific TCR redirected T-cell therapyFH-MCVA2TCR T细胞疗法-弗莱德哈钦森癌症研究中心/bluebird bioAutologous TCR redirected T-cell therapy(MCPyV) TCR-engineered autologous T cellsFH-MCVA2TCR +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionGene transferenceImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Merkel Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics IncFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics IncFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsCarcinoma, Merkel Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A